|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
Marketwire
May 21
Comment
NEW YORK, NY -- (Marketwire) -- 05/21/12 -- The Biotechnology Industry has shown investors some impressive gains this year. The SPDR S&P Biotech ETF (XBI) is up nearly 25 percent year-to-date. A flurry of mergers & acquisitions activity and a growing
Benzinga
May 15
Comment
CytRx Corporation (NASDAQ: CYTR) today announced a reverse split of its common stock at a ratio of 1-for-7. CytRx's common stock will begin trading on NASDAQ on a split-adjusted basis when the market opens on May 16, 2012. The Company's Board of...
StreetInsider.com
May 10
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/CytRx+Corp+%28CYTR%29+Posts+Q1+Loss+of+7cShare/7423513.html for the full story.
Business Wire
May 10
Comment
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2012, and provided a business update. “We are delighted with recent developments that have
Business Wire
May 7
Comment
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced that complete data from the Company’s Phase 1b/2 clinical trial with its proprietary doxorubicin tumor-targeting conjugate INNO-206 in patients
StreetInsider.com
Apr 26
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CytRx+%28CYTR%29+Commences+INNO-206+Phase+2/7375039.html for the full story.
Business Wire
Apr 26
Comment
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual
Business Wire
Apr 23
Comment
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it has received a favorable ruling from the NASDAQ Hearings Panel (the “Panel”), whereby the Panel has granted the Company’s request to
Business Wire
Apr 12
Comment
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a key patent covering the tumor-targeting conjugate INNO-206 linker platform
Marketwire
Mar 23
Comment
NEW YORK, NY -- (Marketwire) -- 03/23/12 -- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation out of Washington boosts the sector's reach. The iShares NASDAQ Biotechnology Index (IBB) is
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
